REFERENCES
- Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429(1-3): 209–29.
- Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3 (6): 359–71.
- Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales"? Clin Microbiol Rev 2000; 13 (4): 615–50.
- Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother 2001; 13 (1): 3–8.
- Cohen J, Abraham E. Microbiologic findings and corre-lations with serum tumor necrosis factor-alpha in patients with severe sepsis and septic shock. J Infect Dis 1999; 180 (1): 116–21.
- Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998; 27 (6): 1497–507.
- Rodriguez JL, Miller CG, DeForge LE, Kelty L, Shanley CJ, Bartlett RH, et al. Local production of interleukin-8 is associated with nosocomial pneumonia. J Trauma 1992; 33 (1): 74-81; discussion 81-2.
- Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumoniae. Infect Immun 1996; 64 (12): 5211–8.
- Laichalk LL, Bucknell KA, Huffnagle GB, Wilkowski JM, Moore TA, Romanelli RJ, et al. Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect Immun 1998; 66 (6): 2822–6.
- Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection 1996; 24 (4): 275–91.
- Giuliani A, Porcelli SA, Tentori L, Graziani G, Testorelli C, Prete SP, et al. Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen. Life Sci 1998; 63 (12): 985–94.
- Tentori L, Graziani G, Porcelli SA, Sugita M, Brenner MB, Madaio R, et al. Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes. Antimicrob Agents Chemother 1998; 42 (3): 550–4.
- Gollapudi S, Jaidka S, Gupta S. Molecular basis of rifampicin-induced inhibition of anti-CD95-induced apoptosis of peripheral blood T lymphocytes: the role of CD95 ligand and FLIPs. J Clin Immunol 2003; 23 (1): 11–22.
- Duncker D, Ullmann U. Influence of various antimicro-bial agents on the chemiluminescence of phagocytosing human granulocytes. Chemotherapy 1986; 32 (1): 18–24.
- Martinez Oliva C, Puente Ranz LF, Gonzalez Roiz C, Munoz Sanz A, Blanco Palenciano J, Blanco Roca MT, et al. [Isoniazid and pyrazinamide: in vitro effect on polymorphonu-clear leukocytes]. Sangre (Barc) 1987; 32 (5): 455–62.
- Zeis BM. Antimycobacterial drugs and the production of reactive oxidants by polymorphonuclear leucocytes in vitro. Chemotherapy 1988; 34 (1): 56–60.
- Demkow U, Malkowska-Zwierz W, Rogala E, Skopinska-Rozewska E, Lewandowski Z. Effect of antitubercu-lous drugs, isoniazid, pyrazinamide and rifampicin, on chemilu-minescence of the human polymorphonuclear leukocytes. Folia Biol (Praha) 1995; 41 (5): 257–62.
- Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagocytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int Immunopharmacol 2003; 3 (4): 513–22.
- Pahlevan AA, Wright DJ, Bradley L, Smith C, Foxwell BM. Potential of rifamides to inhibit TNF-induced NF-kappaB activation. J Antimicrob Chemother 2002; 49 (3): 531–4.
- Caruso I, Montrone F, Fumagalli M, Vernazza M, Santandrea S. Rheumatoid knee synovitis successfully treated with intraarticular Rifamicin SV. Arthritis Rheum 1980; 23 (4): 518–9.
- Caruso I, Principi N, D'Urbino G, Santandrea S, Boccassini L, Montrone F, et al. Rifamycin SV administered by intra-articular infiltrations shows disease modifying activity in patients with pauci- or polyarticular juvenile rheumatoid arthritis. J Int Med Res 1993; 21 (5): 243–56.
- Radossi P, Baggio R, Petris U, De Biasi E, Risato R, Davoli PG, et al. Intra-articular rifamycin in haemophilic arthropathy. Haemophilia 2003; 9 (1): 60–3.